Silver Book Fact

Teriparatide, or human recombinant PTH, has been shown to decrease vertebral fractures by 65% to 69%, and non-vertebral fragility fractures by around 53%.

Neer R, Arnaud C, Zanchetta J, et al. Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis. NEJM. 2001; 344(19): 1434-41. http://content.nejm.org/cgi/content/abstract/344/19/1434

Reference

Title
Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
Publication
NEJM
Publication Date
2001
Authors
Neer R, Arnaud C, Zanchetta J, et al
Volume & Issue
Volume 344, Issue 19
Pages
1434-41
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Clinical studies in nutrition and physical activity interventions have proven that fractures can be prevented, even in older individuals, and that they do not need to be a natural consequence…  
  • Hip fracture prevention in at-risk, postmenopausal women saves $333 million annually.  
  • Risedronate, a bisphosphonate, has been shown to increase vertebral bone mineral density (BMD) by around 5% and hip BMD by 2% to 3% in postmenopausal women with osteoporosis.  
  • A study that looked at a combination of calcium and Vitamin D found that hip fractures were reduced by around 43%.  
  • Teriparatide, or human recombinant PTH, has been shown to decrease vertebral fractures by 65% to 69%, and non-vertebral fragility fractures by around 53%.